" class="no-js "lang="en-US"> B dot Medical - Medtech Alert
Monday, October 07, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
B dot Medical | MTA

B dot Medical

About B dot Medical

B dot Medical
B dot Medical is a startup company originating from the National Institute of Radiological Sciences (NIRS). The company has developed the "ultra-compact proton therapy system" utilizing the advanced technology and experience gained at NIRS. The company is challenging the world with Japanese technological innovation.

Related Story

Diseases

 B dot Medical to Install Ultra-compact Proton Therapy System at Thammasat University in Thailand | MTA

B dot Medical to Install Ultra-compact Proton Therapy System at Thammasat University in Thailand

February 13 2023

B dot Medical and Thammasat University, a leading national university in Thailand, have signed a memorandum […]